CXCL13可预测早期类风湿关节炎的长期影像学状态
本研究在158例未经治疗的早期类风湿关节炎(RA)患者中检测基线血浆CXCL13,并随访11年。基线CXCL13与11年后的总Sharp评分(TSS)及影像学进展(ΔTSS)相关,且预测关节破坏的效能优于CRP、DAS28CRP、SJC28和ACPA状态。
要点
- 基线单次血浆CXCL13可预测早期RA患者11年后的影像学状态与进展。
- CXCL13高于85 pg/ml时,预测11年后TSS≥5的概率为89%。
- CXCL13预测长期关节破坏的效能优于CRP、DAS28CRP、SJC28和ACPA状态。
核心结论
- 在早期RA中,基线单次血浆CXCL13检测在预测长期影像学状态和进展方面优于目前使用的临床和血清学疾病标志物。
研究设计与样本
- 研究纳入158例未经治疗的RA患者并随访11年,检测血浆CXCL13,基线时获取临床和生化DAS及以TSS评估的影像学状态,并纳入年龄和性别匹配的健康对照。
主要发现
- CXCL13在基线时显著升高,治疗过程中下降,但未降至健康对照水平。
- 基线CXCL13与CRP和ESR相关,但与其他疾病活动度标志物无关。
- 基线CXCL13与11年时的TSS及影像学进展(ΔTSS)均相关。
- CXCL13高于85 pg/ml时,以89%的概率预测11年治疗后TSS≥5的风险。
- 与CRP、DAS28CRP、SJC28和ACPA状态相比,CXCL13预测11年关节破坏的效能更优。
关键数值与推荐
- CXCL13高于85 pg/ml预测11年后TSS≥5的概率为89%。
临床怎么用
- 对早期未治疗RA患者,可考虑检测基线血浆CXCL13以辅助识别长期关节破坏高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Identification of RA patients at a high risk of joint destruction remains challenging. The C-X-C motif chemokine 13 (CXCL13) has previously been suggested as a marker of disease activity in RA. Here, we investigate the potential of plasma CXCL13 as a marker of long-term radiographic status and progression. METHODS: CXCL13 was measured in plasma from treatment-naïve RA patients (n = 158) with an 11-year follow-up. At baseline, clinical and biochemical DASs were obtained; among these CRP, ESR, DAS in 28 joints with CRP (DAS28CRP), number of swollen joints (SJC28) and radiographic status, evaluated by total Sharp score (TSS). Age- and gender-matched healthy controls (HCs) were included. RESULTS: CXCL13 was significantly increased at baseline and decreased during treatment; however, it was not reduced to the level in HCs. At baseline, CXCL13 was associated with both CRP and ESR, but not with other markers of disease activity. Baseline CXCL13 was correlated with both TSS and radiographic progression (ΔTSS) at 11 years. With an 89% probability, levels of CXCL13 above 85 pg/ml predicted the risk of a TSS of 5 or above, after 11 years of treatment. Compared with CRP, DAS28CRP, SJC28 and ACPA status, CXCL13 was superior in predicting 11-year joint destruction. CONCLUSION: In early RA, one single measurement of plasma CXCL13 at baseline is superior to currently used clinical and serological disease markers in the prediction of long-term radiographic status and progression.
引用
- Greisen SR, Mikkelsen C, Hetland ML, et al. CXCL13 predicts long-term radiographic status in early rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34636880. doi:10.1093/rheumatology/keab763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。